Korro Bio, Inc.
KRRO Healthcare Biotechnology
Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024. In the quarter to June 2026, revenue fell 86.3%, EPS grew 61.0% and free cash flow grew 12.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KRRO
Korro Bio, Inc. (KRRO) EV/Sales
As of 16 October 2026, Korro Bio, Inc. (KRRO) trades at a EV/Sales of 8.4×. Over the past ten years it has ranged from −2.4× (January 2024) to 42.4× (February 2021); the current reading is higher than 75% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.9× | (56.14%) |
| FY2024 | 6.6× | 283.19% |
| FY2021 | 1.7× | (93.19%) |
| FY2020 | 25.2× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 2.9× | (88.86%) |
| Sep 2025 | 25.9× | 1,091.33% |
| Jun 2025 | 2.2× | (13.56%) |
| Mar 2025 | 2.5× | (53.06%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NKTX Nkarta, Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| CUE Cue Biopharma, Inc. compare | 2.4× |
| KRRO Korro Bio, Inc. | 8.4× |
| ALXO ALX Oncology Holdings Inc. compare | 8.4× |
| MOLN Molecular Partners AG Sponsored ADR compare | 9.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)